Drugs
Conditions
Articles
The pancreatic enzyme replacement therapy Creon 40,000 (pancreatin) is currently unavailable, owing to manufacturing difficulties.
The manufacturer, Abbott, recommends switching patients from Creon 40,000 to Creon 25,000, which will result in a lower pill burden than switching patients to Creon 10,000.
The supply issue is due to the biologic nature of Creon 40,000 and lower-than-expected concentrations of enzymes in porcine glands needed to produce the product. It is not related to any safety issue.
